Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults.
D Taverner, L Bickford, S Shakib...
https://pubmed.ncbi.nlm.nih.gov/10501820/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2025-09-11
80
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the effectiveness and safety of combining oxymetazoline with intranasal corticosteroids for long-term treatment of chronic nasal obstruction that has not improved with standard care. Researchers believe that this combination may reduce nasal blockage more than corticosteroids alone without causing rhinitis medicamentosa, a rebound nasal congestion. Participants will be randomly assigned to one of two groups one receiving a combination of oxymetazoline and budesonide nasal sprays, and the other receiving budesonide nasal spray alone. Both treatments involve applying two sprays in each nostril twice daily for a total of seven weeks. The nasal sprays will be mailed directly to the participants. Additionally, a small group of 10 participants will have nasal tissue biopsies taken at the start and between weeks 4 and 6. During the study, participants will complete surveys about their symptoms at baseline and at weeks 2, 4, 5, 6, and 7. Researchers will monitor how many respond to treatment by week 4 and assess nasal symptoms using specific tools like the Sino-Nasal Outcome Test and Nasal Obstruction Symptom Evaluation. Safety and overall condition will also be evaluated. The total participation period spans seven weeks with regular check-ins to track progress and side effects.
CONDITIONS
Nasal Obstruction With Oxymetazoline and Corticosteroids
N
Nyssa Farrell, MD
S
Sara Kukuljan
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Budesonide + Oxymetazoline Nasal Sprays | Budesonide Nasal Spray |
|---|---|---|
| What it is | Combination of over-the-counter budesonide nasal spray (a corticosteroid) and oxymetazoline nasal spray (an alpha-adrenergic vasoconstrictor), used daily in adults with nasal obstruction who have not improved after steroid therapy. | Budesonide nasal spray is a corticosteroid available over the counter, used for ongoing topical management of nasal obstruction when prior steroid therapy has not been effective. |
| Role in the trial | Tested as the investigational combination to determine whether adding oxymetazoline to budesonide improves nasal obstruction outcomes compared to budesonide alone. | Serves as the active comparator arm, reflecting the current topical steroid approach for patients who have not responded to first-line therapy. |
| Primary use | Intended to reduce nasal obstruction symptoms in adults who have failed a course of topical corticosteroid and are not eligible or interested in surgery. | Aims to maintain or improve nasal breathing in patients with persistent nasal obstruction following unsuccessful topical steroid therapy. |
| How it is given or performed | Participants use both sprays daily, with oxymetazoline and budesonide administered intranasally as per dosing instructions for each OTC product. | Administered daily as intranasal spray according to standard OTC instructions. |
| Evidence status | Combination therapy is undergoing evaluation in randomized trials for nasal obstruction after failed steroid therapy. Prior research shows oxymetazoline plus intranasal steroid improved symptoms compared to steroid alone in chronic rhinitis [75% confidence, strong partial support]. | Topical corticosteroid therapy is widely used for nasal obstruction, but persistent symptoms despite steroids are common. Systematic reviews highlight varying effectiveness and the need for additional options in refractory cases [DIRECT support, 90% confidence]. |
| Important limitations | Long-term use of oxymetazoline nasal spray can cause rebound congestion (rhinitis medicamentosa), limiting its safe duration. Evidence suggests short-term combination may be beneficial, but sustained use carries a risk of mucosal changes and symptom worsening [DIRECT and partial support]. | Corticosteroid nasal sprays may not resolve obstruction in all patients, especially those with persistent symptoms after prior steroid use. Their effectiveness is limited in cases where underlying structural or severe mucosal disease remains [DIRECT support]. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 7 weeks
Participants apply the intranasal spray, either oxymetazoline plus budesonide or budesonide alone, with two sprays in each nostril twice daily.
Questionnaires completed at baseline, Week 2, Week 4, Week 5, Week 6, and Week 7; a subset of participants may have nasal mucosal biopsies at baseline and between Weeks 4 and 6
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
D Taverner, L Bickford, S Shakib...
https://pubmed.ncbi.nlm.nih.gov/10501820/Sarah D Tait, Dorina Kallogjeri, Smrithi Chidambaram...
https://pubmed.ncbi.nlm.nih.gov/31134810/Behram Cam, Murat Sari, Ahmet Midi...
https://pubmed.ncbi.nlm.nih.gov/31468129/Abdullah Tas, Recep Yagiz, Omer Yalcin...
https://pubmed.ncbi.nlm.nih.gov/15806055/R S Kumar, Manish Kumar Jain, Jitendra Singh Kushwaha...
https://pubmed.ncbi.nlm.nih.gov/35712651/Michael J Lipan, Sam P Most
https://pubmed.ncbi.nlm.nih.gov/23846399/A Akerlund, T Klint, L Olén...
https://pubmed.ncbi.nlm.nih.gov/2671220/Joan Busner, Steven D Targum
https://pubmed.ncbi.nlm.nih.gov/20526405/Athanasios Saratziotis, Enzo Emanuelli, Claudia Zanotti...
https://pubmed.ncbi.nlm.nih.gov/32897442/Chun-Yu Lin, Po-Hsu Cheng, Sheen-Yie Fang
https://pubmed.ncbi.nlm.nih.gov/14994772/Washington University School of Medicine
Lead Sponsor